Callitas Health Announces Notice of Allowance for a Biphasic Oral Cannabinoid Patent by U.S. Patent Office, Next Evolution of Cannabis Delivery

Author's Avatar
Apr 25, 2019
Article's Main Image

CINCINNATI, OH / ACCESSWIRE / April 25, 2019 / Callitas Health Inc., (CSE: LILY, OTCQB: MPHMF, FWB: T3F3), (the "Company" or "Callitas") a clinical-stage pharmaceutical development, OTC consumer goods sales & marketing and cannabis delivery development company, today announced its Notice of Allowance for U.S Application Serial Number 16/350,351 from the U.S. Patent and Trademark Office (USPTO) for a new patent on a novel, biphasic oral "candy" that delivers tetrahydrocannabinol (THC) and cannabidiol (CBD) through oral absorption and gut metabolism. A Notice of Allowance is issued after the USPTO determines that a patent can be granted from the company's patent application, filed in November 2018.